Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-L...
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
About this item
Full title
Author / Creator
Yang, James Chih-Hsin, Prof , Shih, Jin-Yuan, MD , Su, Wu-Chou, Prof , Hsia, Te-Chun, MD , Tsai, Chun-Ming, Prof , Ou, Sai-Hong Ignatius, MD , Yu, Chung-Jen, Prof , Chang, Gee-Chen, MD , Ho, Ching-Liang, MD , Sequist, Lecia V, MD , Dudek, Arkadiusz Z, MD , Shahidi, Mehdi, MD , Cong, Xiuyu Julie, PhD , Lorence, Robert M, MD , Yang, Pan-Chyr, Prof and Miller, Vincent A, Dr
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations. Methods In this phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lu...
Alternative Titles
Full title
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
Authors, Artists and Contributors
Author / Creator
Shih, Jin-Yuan, MD
Su, Wu-Chou, Prof
Hsia, Te-Chun, MD
Tsai, Chun-Ming, Prof
Ou, Sai-Hong Ignatius, MD
Yu, Chung-Jen, Prof
Chang, Gee-Chen, MD
Ho, Ching-Liang, MD
Sequist, Lecia V, MD
Dudek, Arkadiusz Z, MD
Shahidi, Mehdi, MD
Cong, Xiuyu Julie, PhD
Lorence, Robert M, MD
Yang, Pan-Chyr, Prof
Miller, Vincent A, Dr
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1011199433
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1011199433
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(12)70086-4
